Here is the design of a clinical trial:

Official Title: Longterm Transfer of FRozen Encapsulated Multidonor Stool Filtrate or Encapsulated Multidonor Microbiome for Chronic Active Ulcerative COlitis

Included conditions:
- Ulcerative Colitis
- Inflammatory Bowel Diseases

Study Armgroups:
- {'label': 'faecal microbiota filtrate', 'type': 'EXPERIMENTAL', 'description': 'Encapsulated faecal microbiota filtrate . 2×5 frozen capsules by mouth on 5 consecutive days per week (5 days on and 2 days off; week 1 - week 12) with water or cool drink.', 'interventionNames': ['Drug: encapsulated faecal microbiota filtrate']}
- {'label': 'faecal microbiota', 'type': 'ACTIVE_COMPARATOR', 'description': 'Encapsulated faecal microbiota. 2×5 frozen capsules by mouth on 5 consecutive days per week (5 days on and 2 days off; week 1 - week 12) with water or cool drink.', 'interventionNames': ['Drug: encapsulated faecal microbiota']}
- {'label': 'Placebo', 'type': 'SHAM_COMPARATOR', 'description': 'Placebo: Encapsulated sterile saline. 2×5 frozen capsules by mouth on 5 consecutive days per week (5 days on and 2 days off; week 1 - week 12) with water or cool drink.', 'interventionNames': ['Drug: Placebo']}

Interventions:
- {'type': 'DRUG', 'name': 'encapsulated faecal microbiota filtrate', 'description': 'Multidonor stool mixed with sterile normal saline, homogenized, filtered, centrifuged, air pressure filtered, encapsulated in hypromellose capsules and frozen.', 'armGroupLabels': ['faecal microbiota filtrate'], 'otherNames': ['FMFT']}
- {'type': 'DRUG', 'name': 'encapsulated faecal microbiota', 'description': 'Multidonor stool mixed with sterile normal saline, homogenized, filtered, encapsulated in hypromellose capsules and frozen.', 'armGroupLabels': ['faecal microbiota'], 'otherNames': ['FMT']}
- {'type': 'DRUG', 'name': 'Placebo', 'description': 'Sterile saline encapsulated in hypromellose capsules and frozen.', 'armGroupLabels': ['Placebo'], 'otherNames': ['Encapsulated sterile saline']}

Primary Outcomes:
- {'measure': 'clinical remission', 'description': 'The primary outcome will be clinical remission at week 12 post first transfer of FMFT or FMT, defined by Mayo score ≤ 2, all subscores ≤ 1; additionally patients unavailable at the week 12 follow-up will be included as non-responders (i.e. counted no remission).', 'timeFrame': '12 weeks'}

Please estimate the sample size based on the assumption: 
The overall power is set at 0.8 (80%) with a global significance level of 0.05 (two-sided). A potential dropout rate of 30% is considered.
Sample size
        Sample size calculations were performed for the primary outcome remission rates 12 weeks post first FMT/FMFT/placebo. The sample size calculation is based on a 2Ã3 table Ï2 test as implemented in nQuery Advisor 7.0 (Ï2 test of equal proportions in G groups (equal nâs)) even though a more complicated model will be used for the confirmatory analysis. Based on this, we estimate the remission rates 12 weeks post first FMT/FMFT to be ÏFMT â30% or ÏFMFT â30% while ÏPlaceboâ5% are expected under placebo. To detect such a clinically relevant benefit at an overall power of 1 â Î² = 0.8 for a global significance level of Î± = 0.05 (two-sided), a sample size of n = 3 Ã 40 = 120 is required for the confirmatory analysis. To account for a potential dropout rate of 30% overall and/or lower power of the more advanced analysis model, the total sample size is n = 3 Ã 58 = 174 patients.
        Table 1 shows the impact of slightly altered planning assumptions regarding the true rates on the global power. Moreover, the table also depicts power estimates for the joint test of FMT/FMFT against placebo and the two-group tests of FMT vs. placebo, FMFT vs. placebo (two group continuity corrected Ï2 test of equal proportions; unequal and equal n). As similar rates are expected for FMT and FMFT, no power estimates are provided for this comparison.
Table 1Statistical power analysisTrue rates [%]Sample size per group (including dropouts)aPower for the respective test setting [%]ÏFMTÏFMFTÏPlaceboGlobal testbFMT and FMFT vs. placeboFMT or FMFT vs. placebo303055893989230401058929569 rsp 9540401058969995aResulting in a total sample size would be 3 Ã 58 = 174, 3 Ã 93 = 279, and 3 Ã 50 = 150 patients to be randomizedbThe increased power (i.e., a power larger than 80%) results from the inclusion of dropouts in the analysis